| Summary: | Dupilumab is a recombinant human monoclonal antibody of the IgG4 class. Its mechanism of action can most broadly be described as inhibition of interleukin 4 and 13-mediated signal transduction. These cytokines are the main drivers of inflammatory diseases such as atopic dermatitis (AD) and asthma. Currently, dupilumab is the subject of many studies and scientific articles. More and more papers are being written about the efficacy of this drug and the side effects. Based on publications from the PubMed database, we present selected cases of atopic dermatitis patients who experienced uncharacteristic and unclear hair-related changes, such as hair loss, growth and change in hair colour, after dupilumab administration.
|
|---|